NeoTX
Shedding a new light on cancer immunotherapies

Learn More

Executive Summary

NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful, yet safe, native antibacterial immune reaction.

The company’s lead STR molecule, Naptumomab estafenatox (NAP), is currently in clinical development for advanced solid tumors (NCT03983954).

Management

Asher Nathan

ASHER NATHAN PhD

CEO, and Co-Founder

Asher Nathan has extensive experience in diverse roles within the industry, including founder, entrepreneur ...

Read more
Marcel Rozencweig M.D.

MARCEL ROZENCWEIG M.D.

CMO

Dr. Rozencweig is a medical oncologist with more than 40 years of experience and accumulated expertise in clinical trials and...

Read more
Ramona Lloyd PhD

RAMONA LLOYD PhD R.A.C.

Chief Regulatory Officer

Dr. Lloyd is a leading regulatory expert with over 25 years of experience in global regulatory affairs and quality assurance. ...

Read more
Robert Harow

ROBERT HAROW

CFO/COO

Prior to co-founding NeoTX, Mr. Harow co-founded Zoticon Bioventures, where ...

Read more
Roger Kornberg PhD

PROF ROGER KORNBERG PhD

Chief Scientist

Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006. Collectively, Dr. Kornberg’s research has revolutionized...

Read more
Dr. Michal Shahar

MICHAL SHAHAR PhD

VP of R&D

Dr. Shahar previously served as VP of Research and Development at Efranat Ltd., an immuno-oncology drug ...

Read more

Board of Directors

J. Tomilson Hill
J. Tomilson Hill is a private investor, whose career has spanned both the investment banking and the asset management business since 1973. Prior to January 2019, Mr. Hill was the President and CEO of Blackstone Alternative Asset Management and Vice Chairman of Blackstone Group where he served as a member of the Board of Directors of Blackstone’s general partner since March 2007. Mr. Hill is a graduate of Harvard College and the Harvard Business School. He is a member of the Council on Foreign Relations where he is Chairman Emeritus of the Investment Committee and serves on the Council’s Investment Committee, and is a member of the Board of Directors of Lincoln Center Theater, where he is Chairman Emeritus. He is Chairman Emeritus of the Hirshhorn Museum and Sculpture Garden in Washington, D.C., and currently serves on the Investment Committee of the Smithsonian Institution and the Executive Committee and the Board of Trustees of The Metropolitan Museum of Art. He also serves on the Board of the Guggenheim Museum, the Telluride Foundation, the Advantage Testing Foundation, the Friends of the High Line, and Our Lady Queen of Angels School, a parochial school (K-8th grade) in Spanish Harlem. He is a member of the Advisory Board of Christie’s and a member of the Board of Directors of First Eagle Investment Management, Hamilton Insurance Group, Limited, Advantage Testing, Inc. and Crux Informatics.

Andrew (W.D) Kim
Mr. Kim has more than 15 years of professional experience managing private equity funds. During his career, he has executed up to $400 million in M&A transactions. Mr. Kim is founder & CEO of Riverstone Investment Co., Ltd., which was formed in 2010, and Chairman of NDFOS (KOSDAQ:238090). Mr. Kim currently serves as a member of the Board of Directors of Immunomet Therapeutics and Zyversa Therapeutics placed in the US. Mr. Kim was formerly Co-founder & CIO at Liberty Investment Co., Ltd. He received a BA in economics from Cornell University.

Paul T. Marinelli
Mr. Marinelli has served as President of Lawrence Investments, LLC, a private equity investment firm that is controlled by Lawrence J. Ellison, since 2015 (and as Vice President from 2004-2015). From 1999 to 2004, he held the position of Corporate Development Group Director at Cadence Design Systems, an electronic design automation software and services company, where he managed several dozen acquisitions and strategic investments. Prior to 1999, Mr. Marinelli held various financial roles at PricewaterhouseCoopers, a global professional services firm, AlliedSignal, an aerospace, automotive and engineering company, and EMCON, an environmental engineering firm. Mr. Marinelli earned a B.S. from the University of California, Berkeley, and an M.B.A. from Cornell University. Mr. Marinelli has served as an officer and/or director of several companies owned by Mr. Ellison, including LeapFrog Enterprises (NYSE: LF), Hawaii Island Air, Tennis Ventures, LLC (owner of the BNP Paribas tennis tournament in Indian Wells, California) and Lanai Resorts, LLC (owner of the Hawaiian island of Lanai).

Robert Harow

Prof Roger Kornberg PHD

Asher Nathan PHD

Science

NeoTX’s Selective T cell Redirection (STR) platform has novel properties designed to increase the response rate of current immunotherapies in solid tumors. By binding bacterial determinants to the tumor surface, the technology effectively converts a weak immune response against cancer to a powerful, but specific, antibacterial immune reaction. STR technology carries the potential to augment the effectiveness of checkpoint inhibitors and other anticancer approaches, including breaking of drug resistance.

Naptumomab estafenatox (NAP), NeoTX’s lead candidate, and the first STR platform drug to enter the clinic, is currently in a Phase 1b clinical trial for advanced and metastatic solid tumor indications. NAP was licensed from Active Biotech (NASDAQ STOCKHOLM: ACTI) in 2016. NAP has significant potential as a monotherapy and in combination with chemotherapy, checkpoint inhibitors and other technologies.

NAP is directed against tumors expressing 5T4 antigen, which is present on many types of cancers, including the most frequent solid tumors.

Previous clinical trials have found NAP to be well-tolerated and demonstrated preliminary signals of efficacy. A Phase 1b clinical trial of NAP is ongoing.

To learn more about the trial (NCT03983954), please visit our clinicaltrials.gov page.

Further drug candidates developed with the STR platform have the potential for value in treating hematologic cancers and additional solid tumor indications such as glioblastoma. While the STR platform is currently in clinical trials in combination with checkpoint inhibitors, STR may enhance other therapeutic modalities. Additionally, NeoTX is actively exploring in-licensing deals and partnerships that could give the company access to new early-stage drugs that could be complementary to the STR platform.

To achieve success,
NeoTX’s strategy for growth is to:

  • Discover, acquire and develop technologies that exploit novel mechanisms that enhance the immune system’s ability to attack tumors
  • Develop business partnerships with STR.
  • Commercialize proprietary products through corporate alliances.
View Press Release

NEWS

February 19, 2020 - Rehovot, Israel
NeoTX Closes $45 Million Series C Financing

NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies, has closed a $45 million Series C financing.  In conjunction with the financing, former vice chairman of The Blackstone Group, J. Tomilson Hill, Chairman of NDFOS Co., Ltd, Andrew Kim, Paul T. Marinelli and Nobel laureate Dr. Roger Kornberg, the chief scientific officer of NeoTX have joined the NeoTX Board of Directors. To date, NeoTX has raised over $60 million. NeoTX plans to use the Series C proceeds to advance its STR platform for the treatment of advanced and metastatic solid tumors as well as to in-license new technologies.

“With the funds raised in this financing, we intend to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox (“Nap”) in combination with durvalumab  and continue to develop our patented STR platform,” said Asher Nathan, chief executive officer of NeoTX. “Our platform, which uniquely leverages the body’s natural antibacterial immune response to selectively redirect T cells to kill the tumor, has the potential to be applicable in a variety of solid tumor indications and in combination with other immunotherapies. We look forward to the clinical advancement of Nap and expanding our platform in order to provide new options to patients suffering from advanced cancers.”

The open-label, multicenter, dose-finding Phase 1b study of Nap (NCT03983954) is currently enrolling. Patients are dosed with a combination of Nap and AstraZeneca’s (NYSE: AZN) checkpoint inhibitor IMFINZI® (durvalumab). NeoTX aims to establish the maximum tolerated dose before advancing to a larger cohort expansion phase in the Unites States.

About NeoTX:
NeoTX is a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The company’s lead STR molecule, naptumomab estafenatox (Nap) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com.

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com

January 9, 2020 - Rehovot, Israel
NeoTX Therapeutics's CEO, Asher Nathan, interviewed by Karen Jagoda on the Empowered Patient Podcast

NeoTX was featured on a popular patient radio podcast.
Dr. Asher Nathan, CEO of NeoTX talks about the company's work developing immunotherapies for a wide range of solid tumors using their proprietary Selective T Cell Redirection (STR) platform. This technology enables therapies that bind a genetically engineered super antigen to the tumor surface which trigger a native, controlled immune response that can kill the cancer with potentially fewer side effects than currently available therapies. Asher discusses the company's lead STR molecule, NAP, which is being developed to treat advanced cancers. NAP, which has potential as both a monotherapy and in combination with checkpoint inhibitors, is currently in a Phase 1B clinical trial in collaboration with AstraZeneca.
Download the transcript here

Nov 4, 2019 - Rehovot, Israel
NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

NeoTX Therapeutics, Ltd. today announced a presentation on the company’s lead candidate from its Selective T cell Redirection (STR) platform, naptumomab estafenatox (Nap), at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.
The poster presentation will highlight preclinical data demonstrating that Nap and checkpoint inhibitors work synergistically to induce a prolonged and protective immune response against solid tumors.

Details on the presentation are as follows:
Abstract Title: Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor
Abstract Number: P657
Presenter: Meir Azulay, Ph.D.
Session Date & Time: Friday, November 8, 2019, 12:30 – 2:00 p.m. and 6:30 – 8:00 p.m. EST
Link to PDF of Poster: Selective T Cell Redirection

About NeoTX:
NeoTX Therapeutics Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology (www.NeoTX.com).

Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
(646) 751-4366
cait@lifescipublicrelations.com

Oct 28, 2019 - Rehovot, Israel
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
Dose-escalation study to determine maximum tolerated dose ahead of Phase 2 cohort expansion study.
Milestone marks initiation of studies in the NeoTX-AstraZeneca collaboration to study Nap in combination with durvalumab.

NeoTX Therapeutics, Ltd. today announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (Nap) in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® (durvalumab) for the treatment of advanced or metastatic solid tumors. The company aims to establish the maximum tolerated dose in the dose-escalation Phase 1b study before advancing to a cohort expansion study.
“The dosing of the first patient in our Phase 1b trial is a significant milestone for NeoTX, as it is our first clinical-stage molecule developed with our Selective T Cell Redirection (STR) platform,” said Asher Nathan, Ph.D., chief executive officer of NeoTX. “Previous clinical studies have shown Nap to be well-tolerated, and preclinical work conducted by the NeoTX team supports its broad potential in treating advanced and metastatic tumors, especially in combination with checkpoint inhibitors. We’re looking forward to bringing this therapy to patients suffering from advanced cancers that have thus far been unresponsive to therapy with checkpoint inhibitors alone.”
The open-label, multicenter, dose-finding Phase 1b trial (NCT03983954) will enroll patients with previously treated advanced or metastatic tumors. Patients will be treated with a combination of Nap and durvalumab.

About the STR platform:
The STR platform leverages the body’s natural antibacterial immune response to selectively expand and redirect T cells to rapidly infiltrate and kill tumor cells, offering unique advantages in the field of T cell redirection. STR compounds induce the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells.

About naptumomab estafenatox (Nap):
Naptumomab estafenatox is the lead compound in NeoTX’s STR platform and is designed to target the 5T4 antigen that is present on many tumors.
Naptumomab estafenatox was licensed from Active Biotech in 2016. Active Biotech AB (publ) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Please visit www.activebiotech.com for more information.

About Durvalumab:
Durvalumab (IMFINZI®) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor's immune-evading tactics and releasing the inhibition of immune responses.
Imfinzi is approved for unresectable, Stage III non-small cell lung cancer (NSCLC) in more than 50 countries including the US, in the EU, and Japan based on the Phase III PACIFIC trial. Imfinzi is also approved for previously-treated patients with advanced bladder cancer in 10 countries, including the US.
As part of a broad development program, Imfinzi is also being tested as a monotherapy and in combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with NSCLC, small cell lung cancer, bladder cancer, head and neck cancer, liver cancer, cervical cancer, biliary tract cancer and other solid tumors.

About NeoTX:
NeoTX Therapeutics Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology (www.NeoTX.com).

Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
(646) 751-4366
cait@lifescipublicrelations.com

Feb 11, 2019 - Rehovot, Israel
NeoTX Therapeutics Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
Collaboration will evaluate the safety and activity of the combination of NeoTX’s naptumomab and AstraZeneca’s durvalumab in selected solid tumors

NeoTX Therapeutics, Ltd announced today that it has entered into a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox (“naptumomab”) in combination with IMFINZI® (durvalumab). These studies are expected to begin in 2019. Naptumomab is the lead drug in NeoTX’s novel Selective T cell Redirection (“STR”) platform.
Naptumomab’s dual mechanism of action coats the tumor with a target that can be easily identified by T cells and then primes and redirects specific activated T cells that can identify that target, to the tumor.
Durvalumab is a human monoclonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and allows activated T cells to attack tumor cells.
The Phase 1b/2 studies will determine the maximum tolerated dose (MTD) of naptumomab in combination with durvalumab, evaluate the clinical response, safety and tolerability of the combination, as well as test for multiple pharmacodynamic parameters.
Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in solid tumors. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. Up to 195 patients are planned to be enrolled in this multicenter, open-label study.
“We are pleased to work with AstraZeneca addressing the high unmet medical need of patients with tumors for which checkpoint inhibitor therapy has had little success,” said Asher Nathan, NeoTX Therapeutics’ Chief Executive Officer. “The safety profile of naptumomab alone and in combination with interferon has been demonstrated in clinical studies in hundreds of patients with solid tumors. Naptumomab can enhance T cell activation and infiltration in tumors and can remodel the immunosuppressive tumor microenvironment. In preclinical models, naptumomab has a synergistic effect with checkpoint inhibitors which could translate into durable responses in patients.”

About NeoTX:
NeoTX Therapeutics Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology (www.NeoTX.com).
For more information contact
609 718 2305
CEO Asher Nathan x215 (asher@neotx.com) or
CFO Robert Harow x204 (robert@neotx.com).
About Naptumomab Estafenatox:
Naptumomab estafenatox is the lead compound in NeoTX’s STR platform. The STR platform offers unique advantages in the field of T cell redirection. STR compounds induce the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells.
Naptumomab estafenatox was licensed from Active Biotech in 2016.
About Active Biotech:
Active Biotech A.B (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer.
About Durvalumab:
Durvalumab, a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumor’s immune-evading tactics and inducing an immune response. As part of a broad development program, durvalumab is being investigated as monotherapy and in combination with immuno-oncology, small molecules, and chemotherapies across a range of tumors and stages of disease.

Various statements in this release concerning future expectations constitute "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may,” "expects,” "anticipates,” "believes,” and "intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors” sections of recent annual reports filed by the parties to this release. In addition, any forward-looking statements represent the parties’ views only as of the date of this release and should not be relied upon as representing their views as of any subsequent date. The parties do not assume any obligation to update any forward-looking statements unless required by law.

April 16, 2018 - Chicago, IL
NeoTX was awarded a poster session at the prestigious AACR conference in Chicago.

The information presented can be found at the following link:
http://www.abstractsonline.com/pp8/#!/4562/presentation/9330

Our Partner has put out the information in a related link
https://www.activebiotech.com/en/media/pressreleases/?id=2183815&date=1523534400

December 2017 - Rehovot Israel
NeoTX is featured in Haaretz Magazine

NeoTX, an Immuno-Oncology drug development company, was featured in the December edition of their business magazine, highlighting Anyara

Anyara is a TTS (Tumor Targeting Superantigen) compund that enhances the ability of the immune system to recognize a tumor.
See the online version on page 41 here. For the pdf download, please click here.

December 2017 - Rehovot Israel
NeoTX closes $8.8MM Series B funding

NeoTX, an Immuno-Oncology drug development company, has raised over $8,750,000 in Series B funding from investors including Starr Ventures, a fund led by former AIG CEO Hank Greenberg.

Total funds raised to date is nearly $18MM.

Biotech entrepreneur CEO, Dr. Asher Nathan, stated "I continue to be extremely proud of the high quality team we have been able to attract, and the faith that our investors have placed in our ability to succeed. We continue to make progress and are excited by the developments in the immuno-oncology market."

October 2016 - Rehovot Israel
NeoTX closes $9.2MM Series A funding

NeoTX, an Immuno-Oncology drug development company, has raised over $9,200,000 in Series A funding from investors including Starr Ventures, a fund led by former AIG CEO Hank Greenberg.

Biotech entrepreneur CEO, Dr. Asher Nathan, stated "I am extremely proud of the high quality senior management team we have been able to attract, and the faith that our Series A investors have placed in our ability to succeed. We are extremely excited by the steps we have been able to accomplish early in our existence."

October 2016
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

Lund (Sweden) and Tel Aviv (Israel), October 26th 2016 – Active Biotech AB (NASDAQ OMX NORDIC: ACTI) and NeoTX Therapeutics Ltd. announced today that they have entered into a licensing agreement for Active Biotech’s investigational compound Naptomumab estafenatox (“ANYARA”) for cancer immunotherapy. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug. This partnership is a key milestone in NeoTX's strategy to bring tumor recognition enhancing therapeutics to the market.

"We are very enthusiastic about our collaboration with Active Biotech. At NeoTX, we are strongly committed to developing innovative immunotherapies for unmet medical needs. "Active Biotech brings to our collaboration outstanding scientific and intellectual capital, and a powerful commitment to positively impact the treatment of cancer," said Asher Nathan, Chief Executive Officer of NeoTX.

Dr. Marcel Rozencweig, Chief Medical Officer of NeoTX and former Head of Global Clinical Oncology Research at BMS said “We are looking forward to developing ANYARA for immuno-oncology applications. We believe that the ANYARA technology is well suited to increase tumor recognition by the immune system and has demonstrated synergistic activity in combination with checkpoint inhibitors in animal models. As such, ANYARA would be attractive in combination with checkpoint inhibitors whose efficacy can be limited by poor tumor recognition”.

“We are excited about the partnership with NeoTX, who we consider as an ideal partner for ANYARA. This partnership constitutes the next step in the clinical development, as well as the commercialization strategy, for the project.” said Tomas Leanderson, President & CEO of Active Biotech.

About the agreement
Under the terms of the agreement, Active Biotech grants NeoTX exclusive rights to develop and commercialize ANYARA worldwide in cancer indications. The total deal value amounts to $71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech will receive $250 000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.

About ANYARA
ANYARA is a TTS (Tumor Targeting Superantigen) compound that increases the ability of the immune system to recognize the tumor. Synergy has been reported in vivo with a combination of ANYARA and a checkpoint inhibitor in an experimental tumor model. Clinically, the development of ANYARA has primarily been focused on cancer indications with a high unmet medical need. Positive data was reported from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer, where ANYARA was studied both as a single agent (monotherapy) and in combination with an established tumor therapy - docetaxel (Taxotere®) - in patients with advanced cancer. The results showed that ANYARA was well tolerated both as monotherapy and in combination with docetaxel, and increased tumor recognition by T cells.

A Phase 2/3 trial of ANYARA in combination with interferon alpha in renal cell cancer demonstrated acceptable safety but did not meet its primary efficacy endpoint in the ITT population. The upcoming clinical trial will be done in combination with drugs that inhibit checkpoint dampening of the immune system, a combination strategy in line with the mode of action of ANYARA and supported by preclinical data.

NeoTX Therapeutics Ltd. is based in Rehovot Israel and is a clinical stage immuno-oncology company. NeoTX was founded to bring safe and effective immunotherapies to cancer patients. Please visit www.neotx.com for more information.

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington’s disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

For further information, please contact:

NeoTX Therapeutics Ltd.
Asher Nathan CEO
Tel: +1 609 718 2305 x 1

Robert Harow, CFO
Tel: +1 609 718 2305 x 2

(Corp.Reg. No. 515220929)
2 Pekeris Street
Rehovot, Israel
Tel: +1 609 718 2305
Tel: +972 3 912 5853

Active Biotech AB
Tomas Leanderson, President and CEO
Tel: +46 46 19 20 95

Hans Kolam, CFO
Tel: +46 46 19 20 44

(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund, Sweden
Tel: +46 46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 am CET on October 26, 2016.

Contact Us

NeoTX
2 Pekeris Street
Rehovot, Israel 7670202
Phone: +1 609 718 2305
Phone: +972 3 912 5853
Fax: +972 8 936 8584

Contact NeoTX

Copyright NeoTX © 2020 | All Rights Reserved